c-Met-IN-29

c-Met-IN-29 (11g) potently inhibits proliferation of MHCC97H liver cancer cells (IC₅₀ = 4.01 nM) and EBC-1 lung cancer cells (IC₅₀ = 3.50 nM) in vitro^[1].
c-Met-IN-29 (5-50 nM) potently suppresses colony formation of MHCC97H liver cancer cells and EBC-1 lung cancer cells, with slightly stronger activity against EBC-1 cells^[1].
c-Met-IN-29 inhibits proliferation of EBC-1 lung cancer cell spheroids (IC₅₀ = 12.63 nM) and MHCC97H liver cancer cell spheroids (IC₅₀ = 20.9 nM) in a concentration-dependent manner^[1].
c-Met-IN-29 (5-50 nM; 24-48 h) inhibits MET phosphorylation in MHCC97H liver cancer cells and EBC-1 lung cancer cells in a time-dependent manner, with no effect on total MET protein levels^[1].
c-Met-IN-29 (5-10 nM; 24 h for adherent cells) induces apoptosis in MHCC97H liver cancer cells and EBC-1 lung cancer cells (and their 3D spheroids) in a concentration-dependent manner, with EC₅₀ values of 32.2 nM and 26.9 nM for MHCC97H and EBC-1 spheroids, respectively^[1].
c-Met-IN-29 (5 nM, 0-24h) potently inhibits migration and invasion of MHCC97H liver cancer cells and EBC-1 lung cancer cells^[1].
c-Met-IN-29 potently inhibits c-Met kinase in a cell-free assay with an IC₅₀ of 1.6 nM^[1].
c-Met-IN-29 shows excellent selectivity for c-Met kinase over 75 other tested tyrosine kinases^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.